XML 36 R25.htm IDEA: XBRL DOCUMENT
v3.23.1

Net Loss Per Share | 3 Months Ended
--- | ---
Mar. 31, 2023
Earnings Per Share [Abstract] |
Net Loss Per Share | 18. Net Loss Per Share Basic net loss per share attributable to common stockholders of BridgeBio is computed by dividing net loss attributable to common stockholders of BridgeBio by the weighted-average number of shares of common stock outstanding. Diluted net loss per share attributable to common stockholders of BridgeBio is computed by dividing net loss by the weighted-average number of shares of common stock outstanding, plus all additional common shares that would have been outstanding, assuming dilutive potential common shares had been issued for other dilutive securities. For the three months ended March 31, 2023 and 2022, diluted and basic net loss per share attributable to common stockholders of BridgeBio was identical since potential common shares were excluded from the calculation, as their effect was anti-dilutive. The following common stock equivalents were excluded from the computation of diluted net loss per share, because including them would have been antidilutive:
| As of March 31, |  |
| 2023 |  |  | 2022 |  |
Unvested RSAs |  | 507,167 |  |  |  | 1,453,153 |  |
Unvested RSUs |  | 10,878,865 |  |  |  | 6,855,291 |  |
Unvested performance-based RSUs |  | 7,875 |  |  |  | 87,538 |  |
Common stock options issued and outstanding |  | 12,262,353 |  |  |  | 11,831,697 |  |
Estimated shares issuable under performance-based milestone compensation arrangements |  | 10,845,633 |  |  |  | 24,875,491 |  |
Estimated shares issuable under the ESPP |  | 42,898 |  |  |  | 78,252 |  |
Assumed conversion of 2027 Notes |  | 12,878,305 |  |  |  | 12,878,305 |  |
Assumed conversion of 2029 Notes |  | 7,702,988 |  |  |  | 7,702,988 |  |
|  | 55,126,084 |  |  |  | 65,762,715 |  |
Our 2029 Notes and 2027 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. As discussed in Notes 8 and 15, we have performance-based milestone compensation arrangements, whose vesting is contingent upon meeting various regulatory and development milestones, with fixed monetary amounts known at inception that can be settled in the form of cash or equity at our sole election, upon achievement of each contingent milestone. The common stock equivalents of such arrangements were estimated as if the contingent milestones were achieved as of the reporting date and the arrangements were all settled in equity.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI https://asc.fasb.org/topic&trid=2144383 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration